Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 1, 2017, Pages 103-112.e2

  de Boer, Ynto S ^a,b   Kosinski, Andrzej S ^c   Urban, Thomas J ^d   Zhao, Zhen ^e   Long, Nanye ^d   Chalasani, Naga ^f   Kleiner, David E ^g   Hoofnagle, Jay H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Database Analysis; Hepatotoxicity; Immune Response; Immunoglobulin; Toxicity

Indexed keywords

ANTINUCLEAR ANTIBODY; HLA DRB1 ANTIGEN; HYDRALAZINE; IMMUNOGLOBULIN G; LIVER ANTIGEN; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; SMOOTH MUSCLE ANTIBODY; SOLUBLE LIVER ANTIGEN; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; AUTOANTIBODY; HLA ANTIGEN;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE FREQUENCY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL DAMAGE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROSPECTIVE STUDY; TOXIC HEPATITIS; ADOLESCENT; BLOOD; COMPLICATION; GENETICS; LONGITUDINAL STUDY; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTIHYPERTENSIVE AGENTS; AUTOANTIBODIES; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; HEPATITIS, AUTOIMMUNE; HLA ANTIGENS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 85006826688     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.05.043     Document Type: Article

References (35)

1. 1 Wei, G., Bergquist, A., Broomé, U., et al. Acute liver failure in Sweden: etiology and outcome. J Intern Med 262 (2007), 393–401.
2. 2 Björnsson, E.S., Bergmann, O.M., Björnsson, H.K., et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144 (2013), 1419–1425.
3. 3 Reuben, A., Koch, D.G., Lee, W.M., et al. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 52 (2010), 2065–2076.
4. 4 Alvarez, F., Berg, P.A., Bianchi, F.B., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (1999), 929–938.
5. 5 Hennes, E.M., Zeniya, M., Czaja, A.J., et al. Hepatology 48 (2008), 169–176.
6. 6 Suzuki, A., Brunt, E.M., Kleiner, D.E., et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 54 (2011), 931–939.
7. 7 Czaja, A.J., Drug-induced autoimmune-like hepatitis. Dig Dis Sci 56 (2011), 958–976.
8. 8 Bernal, W., Ma, Y., Smith, H.M., et al. The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol 47 (2007), 664–670.
9. 9 Weiler-Normann, C., Schramm, C., Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol 55 (2011), 747–749.
10. 10 Castiella, A., Zapata, E., Lucena, M.I., et al. Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease. World J Hepatol 6 (2014), 160–168.
11. 11 Licata, A., Maida, M., Cabibi, D., et al. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. Dig Liver Dis 46 (2014), 1116–1120.
12. 12 Björnsson, E., Talwalkar, J., Treeprasertsuk, S., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 51 (2010), 2040–2048.
13. 13 van Gerven, N.M., Verwer, B.J., Witte, B.I., et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol 58 (2013), 141–147.
14. 14 de Boer, Y.S., van Gerven, N.M., Zwiers, A., et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 147 (2014), 443–452.
15. 15 van Gerven, N.M., de Boer, Y.S., Zwiers, A., et al. HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes Immun 16 (2015), 247–252.
16. 16 Donaldson, P.T., Doherty, D.G., Hayllar, K.M., et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 13 (1991), 701–706.
17. 17 Oliveira, L.C., Porta, G., Marin, M.L., et al. Autoimmune hepatitis, HLA and extended haplotypes. Autoimmun Rev 10 (2011), 189–193.
18. 18 Chalasani, N., Bonkovsky, H.L., Fontana, R., et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 148 (2015), 1340–1352.
19. 19 Rockey, D.C., Seeff, L.B., Rochon, J., et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 51 (2010), 2117–2126.
20. 20 Fontana, R.J., Watkins, P.B., Bonkovsky, H.L., et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 32 (2009), 55–68.
21. 21 Hayashi, P.H., Barnhart, H.X., Fontana, R.J., et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int 35 (2015), 1623–1632.
22. 22 Kleiner, D.E., Chalasani, N.P., Lee, W.M., et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 59 (2014), 661–670.
23. 23 Zheng, X., Shen, J., Cox, C., et al. HIBAG–HLA genotype imputation with attribute bagging. Pharmacogenomics J 14 (2014), 192–200.
24. 24 Gragert, L., Madbouly, A., Freeman, J., et al. Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. Hum Immunol 74 (2013), 1313–1320.
25. 25 Available at: http://allelefrequencies.net/. Accessed January 21, 2016.
26. 26 Available at: http://livertox.nih.gov/index.html. Accessed January 5, 2016.
27. 27 Stricker, B.H., Blok, A.P., Claas, F.H., et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 8 (1988), 599–606.
28. 28 Malcolm, A., Heap, T.R., Eckstein, R.P., et al. Minocycline-induced liver injury. Am J Gastroenterol 91 (1996), 1641–1643.
29. 29 Goldstein, N.S., Bayati, N., Silverman, A.L., et al. Minocycline as a cause of drug-induced autoimmune hepatitis: report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 114 (2000), 591–598.
30. 30 Toghill, P.J., Smith, P.G., Benton, P., et al. Methyldopa liver damage. Br Med J 3 (1974), 545–548.
31. 31 Maddrey, W.C., Boitnott, J.K., Severe hepatitis from methyldopa. Gastroenterology 68 (1975), 351–360.
32. 32 Forster, H.S., Hepatitis from hydralazine. N Engl J Med, 302, 1980, 1362.
33. 33 Meroni, P.L., Schur, P.H., ANA screening: an old test with new recommendations. Ann Rheum Dis 69 (2010), 1420–1422.
34. 34 Frenzel, C., Herkel, J., Lüth, S., et al. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol 101 (2006), 2731–2736.
35. 35 Temple, R., Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 15 (2006), 241–243.